TipRanks
Go Ultimate55% OFF

ScandiDos AB (SDOS) AI Stock Analysis

SE:SDOS

ScandiDos AB

(Nasdaq OMX AB:SDOS)

Select Model
Rating:45Neutral
Price Target:SEK 0.58â–²(2.68% Upside)
Action:reiterated
Date:10/02/26

The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and negative operating/free cash flow). Technicals add further pressure with a clear downtrend and negative momentum, despite oversold readings. Valuation is difficult to support using P/E due to negative earnings and there is no dividend yield data to offset risk.

Positive Factors
Conservative Balance SheetVery low reported debt relative to equity gives ScandiDos financial flexibility and reduces near-term solvency pressure. This strengthens resilience while the company works to improve profitability, although continued losses could gradually weaken the equity base if they persist.
Negative Factors
Declining RevenueDeclining revenue indicates weakening commercial momentum and limits the scale available to absorb fixed operating costs. Unless growth returns, continued contraction can delay the path to profitability, constrain investment capacity, and make future earnings less predictable.

ScandiDos AB (SDOS) vs. iShares MSCI Sweden ETF (EWD)

-50%-40%-30%-20%-10%0%10%20%SE:SDOS-47.17%EWD+13.33%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
SEK 39.91M
Dividend Yield
―
Average Volume (3M)
72.72K
Price to Earnings (P/E)
-4.6
Beta (1Y)
0.39
Revenue Growth
-19.44%
EPS Growth
-475.48%
Country
Sweden
Employees
25
Sector
General
Sector Strength
55
Industry
Medical - Devices

ScandiDos AB Business Overview & Revenue Model

Company Description

ScandiDos AB (publ), together with its subsidiaries, provides measurement phantoms and software solutions for the quality assurance and validation of dynamic and modulated treatments adopted in clinics in the United States, Europe, Asia, and internat...

How the Company Makes Money

ScandiDos makes money primarily by selling radiation therapy QA products and related software to hospitals and radiotherapy clinics. Key revenue streams typically include: (1) hardware/system sales of measurement and verification equipment used in ra...

ScandiDos AB Financial Statement Overview

Summary

Weak fundamentals dominate: TTM revenue fell (-8.0%), operating profit and net income remain negative (net margin ~-6.3%), and cash flow is still negative (CFO -2.8m; FCF -4.5m). Offsetting this, the balance sheet is conservatively financed with very low debt relative to equity, and gross margin improved sharply in TTM (~56%), but profitability and self-funding are not yet established.

Income Statement

27Negative

Balance Sheet

63Positive

Cash Flow

32Negative
Financial statement breakdown
BreakdownTTMApr 2025Apr 2024Apr 2023Apr 2023Apr 2021
Income Statement
Total Revenue49.97M54.22M60.43M61.55M60.43M59.99M
Gross Profit28.15M-2.71M47.55M52.95M47.55M49.73M
EBITDA-5.05M-439.00K-11.77M-3.00M-11.11M2.85M
Net Income-8.21M-3.44M-14.65M-9.12M-14.65M-1.40M
Balance Sheet
Total Assets72.08M65.97M73.38M72.42M81.47M77.16M
Cash, Cash Equivalents and Short-Term Investments16.00M4.36M10.06M3.55M1.53M9.00M
Total Debt2.32M000083.00K
Total Liabilities24.92M24.31M28.40M30.77M37.19M31.98M
Stockholders Equity47.16M41.66M44.98M41.65M44.29M45.18M
Cash Flow
Free Cash Flow-4.50M-6.79M-2.71M-16.31M-1.46M4.08M
Operating Cash Flow-2.79M-2.92M230.00K-11.90M1.49M8.64M
Investing Cash Flow-3.84M-3.87M-2.94M-4.37M-2.94M-4.63M
Financing Cash Flow11.66M0012.33M0-1.66M

ScandiDos AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.56

Price Trends

50DMA0.71Negative
100DMA0.78Negative
200DMA0.88Negative

Market Momentum

MACD-0.04Negative
RSI31.15Neutral
STOCH21.21Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SDOS, the sentiment is Negative. The current price of 0.56 is below the 20-day moving average (MA) of 0.59, below the 50-day MA of 0.71, and below the 200-day MA of 0.88, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 31.15 is Neutral, neither overbought nor oversold. The STOCH value of 21.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SDOS.

ScandiDos AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:SDOS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:SECT.BSE:SECT.B79OutperformSEK 67.51B105.8130.26%0.38%13.94%5.70%
SE:PAXSE:PAX60NeutralSEK 1.54B-303.85-1.22%―34.05%-144.96%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:SDOSSE:SDOS45NeutralSEK 39.91M-4.57――-19.44%-475.48%
SE:OSSDSE:OSSD44NeutralSEK 373.36M-7.46――-2.61%-0.28%
SE:SPECSE:SPEC40UnderperformSEK 20.68M-0.12-57.15%――16.02%
SE:SCIBSE:SCIB39UnderperformSEK 174.38M-0.78-303.61%―51.21%42.24%

* General Sector Average

Performance Comparison

-50%0%50%SE:SDOSSE:PAXSE:SCIBSE:SPECSE:SECT.BSE:OSSDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
SE:SDOS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:SDOSScandiDos AB0.56-0.52-48.15%
SE:PAXPaxman AB66.30-1.10-1.63%
SE:SCIBSciBase Holding AB12.35-13.24-51.74%
SE:SPECSpectraCure AB0.01-0.13-90.21%
SE:SECT.BSectra AB Class B346.0049.1716.56%
SE:OSSDOssDsign AB3.38-9.51-73.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 02, 2026